Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
rhGH in Adult Short Bowel Syndrome
NCT07691125Phase 4Recruiting
- Sponsor
- Changchun GeneScience Pharmaceutical Co., Ltd.
- Start
- Jul 2024
- Primary completion
- Apr 2027
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial in short bowel syndrome (SBS), sponsored by Changchun GeneScience Pharmaceutical Co., Ltd. Primary endpoint: Change from baseline in total volume of parenteral nutrition (PN/IV) support at 4 weeks. Started Jul 2024; status: recruiting.
02
Conditions
short bowel syndrome (SBS)
Beyond the preview
Go deeper on NCT07691125.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07691125.